Neuralstem Provides Business Update and Reports Second Quarter 2018 Fiscal Results

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

Neuralstem Appoints Jim Scully as Interim Chief Executive Officer

Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke

Neuralstem Announces Presentation of Preclinical Data Demonstrating Neurogenic Compound NSI-189 Improves Cognition and Anxiety in a Mouse Model of Alzheimer’s Disease

Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury

Neuralstem’s NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete paraplegia

Neuralstem to Participate at the BIO 2018 International Convention

Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results

Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology